Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Intra-Cellular Therapies	Xencor	Ligand Pharmaceuticals	Global Blood Therapeutics	Rocket Pharmaceuticals
Symbol	NASDAQ:ITCI	NASDAQ:XNCR	NASDAQ:LGND	NASDAQ:GBT	NASDAQ:RCKT
Price Information
Current Price	$37.86	$38.55	$123.88	$35.46	$40.94
52 Week Range	Buy	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	1.7	1.6	1.6	1.8	1.4
Analysis Score	3.5	4.4	3.4	4.4	3.5
Community Score	2.6	3.1	2.9	3.0	2.9
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	1.7	0.0	0.0	0.8	0.8
Earnings & Valuation Score	0.6	0.6	1.9	0.6	0.0
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Buy
Consensus Price Target	$47.43	$51.13	$214.00	$85.12	$59.18
% Upside from Price Target	25.27% upside	32.62% upside	72.75% upside	140.04% upside	44.56% upside
Trade Information
Market Cap	$3.07 billion	$2.24 billion	$2.06 billion	$2.21 billion	$2.53 billion
Beta	1.5	0.8	1.46	1.39	2.05
Average Volume	596,133	226,771	459,569	963,089	495,816
Sales & Book Value
Annual Revenue	$60,000.00	$156.70 million	$120.28 million	$2.11 million	N/A
Price / Sales	51,238.46	14.32	17.15	1,046.44	N/A
Cashflow	N/A	$0.50 per share	$6.67 per share	N/A	N/A
Price / Cash	N/A	77.84	18.58	N/A	N/A
Book Value	$3.52 per share	$10.46 per share	$43.68 per share	$9.61 per share	$6.10 per share
Price / Book	10.76	3.69	2.84	3.69	N/A
Profitability
Net Income	$-147,720,000.00	$26.88 million	$629.30 million	$-266,770,000.00	$-77,270,000.00
EPS	($2.68)	$0.46	$2.11	($4.71)	($1.58)
Trailing P/E Ratio	N/A	N/A	N/A	N/A	N/A
Forward P/E Ratio	N/A	N/A	24.43	N/A	N/A
P/E Growth	N/A	N/A	1.46	N/A	N/A
Net Margins	-1,985.32%	-113.40%	-11.23%	-332.94%	N/A
Return on Equity (ROE)	-48.27%	-13.56%	5.90%	-56.43%	-35.81%
Return on Assets (ROA)	-42.56%	-12.03%	3.22%	-39.32%	-27.52%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	N/A	0.65%	0.16%	0.25%
Current Ratio	19.59%	9.08%	20.28%	7.63%	7.30%
Quick Ratio	19.51%	9.08%	19.96%	7.20%	7.30%
Ownership Information
Institutional Ownership Percentage	79.10%	N/A	N/A	N/A	N/A
Insider Ownership Percentage	18.20%	3.66%	10.60%	4.30%	41.40%
Miscellaneous
Employees	383	202	155	389	91
Shares Outstanding	81.20 million	58.23 million	16.65 million	62.27 million	61.78 million
Next Earnings Date	8/9/2021 (Estimated)	8/3/2021 (Estimated)	8/2/2021 (Estimated)	8/4/2021 (Estimated)	8/4/2021 (Estimated)
Optionable	Optionable	Optionable	Optionable	Optionable	Optionable

Source	Headline
	Rocket Pharmaceuticals Announces Positive Data From RP-L102, RP-L201 Gene Therapy Programs finance.yahoo.com - May 14 at 2:23 AM
	Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Director Sells $29,021,750.00 in Stock americanbankingnews.com - May 13 at 9:44 PM
	BRIEF-Rocket Pharmaceuticals Presents Positive Clinical Data At Annual Meeting Of The American Society of Gene and Cell Therapy msn.com - May 13 at 12:43 PM
	Rocket Pharmaceuticals Presents Positive Clinical Data from Fanconi Anemia, Leukocyte Adhesion Deficiency-I, and Pyruvate Kinase Deficiency Programs a us.acrofan.com - May 13 at 7:42 AM
	Rocket Pharmaceuticals Presents Positive Clinical Data from Fanconi Anemia, Leukocyte Adhesion Deficiency-I, and Pyruvate Kinase Deficiency Programs at 24th Annual Meeting of the American Society of Gene and Cell Therapy finance.yahoo.com - May 13 at 7:42 AM
	Valkyrie’s Punk Rocket skin now available in Apex Legends through Twitch’s Prime Gaming msn.com - May 12 at 4:40 PM
	Rocket Lab to recover Electron booster from ocean after Saturday launch msn.com - May 12 at 4:40 PM
	Rocket.net Managed WordPress Hosting Platform Receives Strategic Investment from HostPapa wfmz.com - May 12 at 11:40 AM
	Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) surprises bears, looks strong going forward marketingsentinel.com - May 12 at 11:40 AM
	First-Hand Account of EMT Who Treated Cardiac Arrest Patient under Rocket Attack jewishpress.com - May 12 at 6:39 AM
	Rocket Lab Readies For Upgraded Reusable Electron Tests aviationweek.com - May 12 at 6:39 AM
	Chardan Capital Stick to Their Buy Rating for Rocket Pharmaceuticals investing.com - May 12 at 6:39 AM
	Demchenko, Ylonen push Rocket over Marlies tsn.ca - May 11 at 10:51 PM
	White House Condemns Ongoing Rocket Attacks by Hamas Against Israel usnews.com - May 11 at 5:50 PM
	Netanyahu Says Gaza Militants Will Pay 'Very Heavy Price' Over Rocket Fire usnews.com - May 11 at 5:50 PM
	Israeli Civilians Under Rocket Fire as Palestinians Launch More Than 500 Missiles jewishjournal.com - May 11 at 5:50 PM
	Rocket Lab prepares to recover second booster at sea after May 15 launch news.yahoo.com - May 11 at 5:50 PM
	Rocket Lab to use parts from previous launch on next mission stuff.co.nz - May 11 at 5:50 PM
	RCKT Makes Notable Cross Below Critical Moving Average nasdaq.com - May 11 at 5:50 PM
	EU Condemns Palestinian Rocket Fire Into Israel, Calls for De-Escalation usnews.com - May 11 at 12:50 PM
	Esports Technologies adds Rocket League To Its International Betting Platform apnews.com - May 11 at 12:50 PM
	Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Down 7.9% americanbankingnews.com - May 11 at 11:39 AM
	Rocket Pharmaceuticals (NASDAQ:RCKT) Announces Quarterly Earnings Results americanbankingnews.com - May 11 at 11:02 AM
	The Latest: Israeli Media Says Rocket Struck Empty School usnews.com - May 11 at 7:49 AM
	Palestinian Rocket Fire, Israeli Strikes in Gaza Run Into Second Day usnews.com - May 11 at 2:35 AM
	Rocket Pharmaceuticals (NASDAQ:RCKT) Upgraded to Hold at Zacks Investment Research marketbeat.com - April 29 at 3:51 AM

Date	Company	Brokerage	Action
12/29/2020	Intra-Cellular Therapies	Cantor Fitzgerald	Boost Price Target
12/15/2020	Intra-Cellular Therapies	Bank of America	Initiated Coverage
12/10/2020	Intra-Cellular Therapies	The Goldman Sachs Group	Initiated Coverage
11/2/2020	Intra-Cellular Therapies	Royal Bank of Canada	Lower Price Target
11/2/2020	Intra-Cellular Therapies	BTIG Research	Lower Price Target
10/5/2020	Intra-Cellular Therapies	Canaccord Genuity	Reiterated Rating
9/9/2020	Intra-Cellular Therapies	JMP Securities	Boost Price Target
2/19/2020	Intra-Cellular Therapies	Evercore ISI	Initiated Coverage
1/31/2020	Intra-Cellular Therapies	JPMorgan Chase & Co.	Downgrade
9/10/2019	Intra-Cellular Therapies	SVB Leerink	Reiterated Rating
8/12/2019	Intra-Cellular Therapies	Jefferies Financial Group	Initiated Coverage
7/8/2019	Intra-Cellular Therapies	Cowen	Reiterated Rating
5/6/2021	Xencor	Wedbush	Lower Price Target
3/2/2021	Xencor	Raymond James	Upgrade
2/24/2021	Xencor	Barclays	Boost Price Target
8/5/2020	Xencor	Mizuho	Reiterated Rating
7/8/2020	Xencor	Piper Sandler	Reiterated Rating
5/10/2020	Xencor	Nomura	Reiterated Rating
2/25/2020	Xencor	Guggenheim	Upgrade
4/14/2021	Ligand Pharmaceuticals	Stephens	Initiated Coverage
2/4/2021	Ligand Pharmaceuticals	Craig Hallum	Boost Price Target
2/4/2021	Ligand Pharmaceuticals	Roth Capital	Boost Price Target
2/4/2021	Ligand Pharmaceuticals	HC Wainwright	Boost Price Target
7/14/2020	Ligand Pharmaceuticals	Benchmark	Boost Price Target
3/24/2020	Ligand Pharmaceuticals	Argus	Downgrade
3/17/2021	Global Blood Therapeutics	Wolfe Research	Initiated Coverage
2/25/2021	Global Blood Therapeutics	William Blair	Downgrade
12/16/2020	Global Blood Therapeutics	Morgan Stanley	Lower Price Target
11/9/2020	Global Blood Therapeutics	Truist	Lower Price Target
11/6/2020	Global Blood Therapeutics	Stifel Nicolaus	Lower Price Target
11/6/2020	Global Blood Therapeutics	Oppenheimer	Lower Price Target
2/25/2021	Rocket Pharmaceuticals	Needham & Company LLC	Initiated Coverage
12/15/2020	Rocket Pharmaceuticals	UBS Group	Initiated Coverage
12/8/2020	Rocket Pharmaceuticals	Chardan Capital	Boost Price Target
10/16/2020	Rocket Pharmaceuticals	Lifesci Capital	Reiterated Rating
8/5/2020	Rocket Pharmaceuticals	Ci Capital	Reiterated Rating

(Data available from 5/14/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources